Small Fiber Neuropathy Testing: 7 Essential Facts for Physicians

Small fiber neuropathy testing is the group of studies used to evaluate the thinly myelinated A-delta fibers and the unmyelinated C fibers in patients who report burning, tingling, numbness, or itching that a standard nerve conduction study cannot explain. Three methods carry most of the clinical weight: skin biopsy with intraepidermal nerve fiber density quantification, quantitative sudomotor axon reflex testing (QSART), and autonomic function studies that measure the sweat response. Distal leg skin biopsy remains the reference standard, with reported sensitivity near 88 percent, and the European Federation of Neurological Societies and the Peripheral Nerve Society both recommend it as the primary objective test.

For an independent practice, the practical question is narrower. Most physicians are not going to send a 3 mm punch biopsy from a primary care exam room. They want to know which patients warrant referral, what an in-office autonomic study can and cannot tell them, and how the pieces fit together into a defensible record. This guide answers those questions in the order they usually come up.

What is small fiber neuropathy testing, and when is it indicated?

Small fiber neuropathy testing is indicated when a patient presents with documented sensory symptoms in a pattern the large fiber examination does not account for. The classic picture is symmetric stocking and glove sensory loss that begins in the feet, described as burning, tingling, numbness, itching, or a sunburn-like quality. Symptoms are frequently worse at the end of the day, and sensitivity to bedsheets is common enough that it has been used as an outcome measure in clinical trials.

Pattern matters as much as severity. A length-dependent presentation that starts distally and moves proximally is the usual course. A non-length-dependent pattern, where symptoms appear on the face, trunk, or arms without a clear distal gradient, points toward an immune cause such as Sjogren syndrome and generally warrants a different workup.

Small fiber neuropathy testing follows symptoms. It is not a wellness add-on and it is not appropriate for asymptomatic patients without a documented risk indication. That distinction is the single most important boundary in this space, both clinically and from a documentation standpoint.

Why do nerve conduction studies come back normal?

This is the question that sends most physicians looking for small fiber neuropathy testing in the first place. A patient describes significant burning pain, the electromyography and nerve conduction study return normal, and the record now contains a negative result that does not match the complaint.

Nerve conduction studies measure conduction along large myelinated fibers. Small fiber neuropathy, by definition, affects the small thinly myelinated and unmyelinated fibers those studies do not sample. A normal nerve conduction study is therefore not evidence against the condition. It is part of the published diagnostic framework: clinical features consistent with small fiber involvement, normal nerve conduction velocity studies, and an abnormal result on a test that actually samples small fibers.

Understanding that hierarchy changes how the negative result gets documented. It is the finding that makes small fiber neuropathy testing appropriate, not a dead end.

Which fiber does each small fiber neuropathy testing method evaluate?

The manufacturer documentation behind the diagnostic devices HealthWright Technologies distributes lays this out more cleanly than most clinical summaries do. LD Technology’s result reading guidelines, part of the instructions-for-use library that ships with the system, map peripheral distal neuropathy to four distinct targets and pair each one with the procedure that samples it.

The same document adds a point with real clinical consequence. C fibers are unmyelinated, so they carry no protective sheath, and they are usually affected before the myelinated nerves are. That ordering explains why a patient can have convincing symptoms, an intact monofilament exam, and a normal nerve conduction study all at once. Each of those procedures is looking at a fiber population that has not been involved yet.

It also explains why sudomotor testing and the sweat response it measures occupy the position they do in a small fiber workup. Sudomotor studies sample the C fiber population directly rather than inferring its status from a neighboring one.

How do the main small fiber neuropathy testing methods compare?

Skin biopsy is the reference standard among small fiber neuropathy testing methods, as summarized in the Cleveland Clinic Journal of Medicine review of the office approach. A 3 mm punch specimen is taken from the distal leg, commonly with a second site at the thigh, and stained with PGP 9.5 so intraepidermal nerve fiber density can be counted against established norms. Reported sensitivity sits near 88 percent. Skin biopsy can also assess sweat gland innervation, where published sensitivity runs roughly 80 to 96 percent with specificity around 90 percent for autonomic involvement.

QSART measures sweat volume produced in response to acetylcholine and reports sensitivity of roughly 73 to 80 percent for distal small fiber neuropathy, which is broadly comparable to biopsy. Its practical limitation is availability. QSART requires dedicated equipment and controlled conditions, and it is concentrated in academic autonomic laboratories rather than community practices.

Office-based autonomic studies sit in a third position. They evaluate sudomotor and cardiovagal function under defined conditions and produce results the same day, which makes them useful for characterizing autonomic involvement and for deciding who needs referral. They do not replace biopsy, and no responsible reading of the literature positions them as a substitute for it. The honest framing is that small fiber neuropathy testing is layered, and each layer answers a different question.

Why do test conditions change a sudomotor result?

Sudomotor measurements are unusually sensitive to how the test is run, and this is where in-office results most often go wrong. LD Technology’s protocol documentation is specific about two conditions.

The patient is measured lying down. Sitting and standing both introduce sympathetic stimulation of their own, and the point of the measurement is to capture a response attributable to the electrical stimulation rather than to posture. Room temperature is held between 73 and 75 degrees Fahrenheit. Warmer than that and the sweat glands activate from heat alone; colder and vasoconstriction distorts the reading in the other direction.

Neither condition is difficult to meet. Both are easy to skip when a room is running behind, and a practice that skips them will accumulate results it cannot interpret. If your staff will be performing these studies, the environmental and positioning requirements belong in the written procedure, not in someone’s memory. The same discipline applies to autonomic nervous system testing generally, where preparation drives a large share of result quality in small fiber neuropathy testing.

What underlying causes should you work up in parallel?

An abnormal small fiber neuropathy testing result is only half the encounter. The other half is identifying why, because a meaningful share of cases are secondary to a condition that can be treated on its own terms.

• Diabetes and impaired glucose tolerance, the most common identifiable cause, accounting for roughly a third of cases with an established etiology
• Sjogren syndrome, which accounts for approximately 10 percent and is more likely when the pattern is non-length-dependent
• Vitamin B12 deficiency
• Celiac disease
• Thyroid dysfunction, renal disease, and liver disease

HIV and hepatitis C also appear in the standard first-line workup. In patients with diabetes, small fiber neuropathy testing sits naturally alongside the structured diabetic foot exam, and abnormal autonomic findings frequently prompt a closer look at cardiovascular involvement. Cardiovascular autonomic neuropathy testing covers that adjacent territory, since autonomic dysfunction rarely confines itself to one organ system.

How does in-office small fiber neuropathy testing fit a practice workflow?

The CMAT Advantage package from HealthWright Technologies is built on FDA-cleared component devices manufactured by LD Technology. The autonomic study runs 7 to 10 minutes and includes sudomotor testing along with the cardiac autonomic reflex battery. The system is on-premises. Results are generated on the unit in the office and printed or saved to the chart during the same visit, which is what makes it usable inside a normal appointment slot rather than a separate visit.

Sudomotor testing is reported under CPT 95923. Coverage is governed by your Medicare Administrative Contractor’s local coverage determination, published in the CMS Medicare Coverage Database, and the documentation requirements are where practices get into difficulty, not the code itself. Confirm the current policy with your MAC before you build a workflow around it, and see our overview of autonomic function testing CPT codes for how the related codes relate to one another.

Two documentation habits matter more than anything else. Record the symptoms that prompted the study before the study happens, and record how the result changed clinical management afterward. Testing that is ordered on a schedule rather than on an indication is the pattern that draws enforcement attention, and it is entirely avoidable. Practices evaluating the underlying hardware can review the TM-Flow system used in CMAT Advantage for the component detail.

Frequently asked questions about small fiber neuropathy testing

Can small fiber neuropathy be confirmed without a skin biopsy?

Not on its own. Published criteria for small fiber neuropathy testing treat distal leg skin biopsy with intraepidermal nerve fiber density quantification as the reference standard, and professional society guidance recommends it as the primary objective test. Autonomic and sudomotor studies are described in the literature as secondary or adjunctive. They can support the clinical picture and characterize autonomic involvement, but the confirmatory role belongs to biopsy.

Does a normal monofilament exam rule out small fiber involvement?

No. The 10-gram monofilament exam assesses large myelinated fibers, which the ADA Standards of Care classify under large-fiber function. C fibers are unmyelinated and are typically affected earlier, so a patient can have an intact monofilament exam and still have documented C fiber dysfunction on sudomotor testing. The two procedures sample different populations.

How long does an in-office autonomic study take?

The CMAT Advantage autonomic study takes 7 to 10 minutes of patient time. It requires the patient to be positioned lying down in a room held between 73 and 75 degrees Fahrenheit, so the room needs to be available for the duration rather than shared mid-test.

Which CPT code applies to sudomotor testing?

CPT 95923 describes autonomic nervous system function testing of sudomotor function. Coverage, frequency limits, and documentation requirements are set by your Medicare Administrative Contractor through its local coverage determination, so confirm the current policy in your jurisdiction before relying on it.

Which patients should be referred rather than tested in the office?

Referral is appropriate when the presentation is non-length-dependent, when symptoms progress rapidly, when there is motor involvement, or when the clinical picture suggests an immune or inflammatory cause that requires serology and specialist management. In-office small fiber neuropathy testing helps characterize the autonomic component, and it can inform who needs that referral, but it does not substitute for one.

Adding autonomic testing to your practice

HealthWright Technologies has supplied diagnostic and therapeutic devices to independent physicians since 2000, with training, implementation support, and billing guidance included rather than sold separately. If you are evaluating whether in-office small fiber neuropathy testing fits your patient population, we can walk through the clinical workflow, the documentation requirements, and the staffing model with you before you commit to anything.

Reach us at contact@healthwrighttechnologies.com or (678) 322-7146, or use the contact page to request a conversation. Our office is at 60 Bear Creek Marina Rd, Mansfield, GA 30055.

This article is provided for physician education and does not constitute medical advice. Consult your healthcare provider before starting any new treatment. Diagnostic decisions remain the responsibility of the treating clinician.

CPT is a registered trademark of the American Medical Association. All CPT codes, descriptions, and published rates are the property of the AMA and CMS respectively. Coding and coverage requirements vary by Medicare Administrative Contractor; confirm current local coverage determination requirements before billing.